Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antidepressants for glycemic control in type 2 diabetes with depression
IRCT20240911063012N1Phase 3Completed
- Sponsor
- Islamic Azad University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of citalopram, escitalopram and sertraline in major depressive disorder (MDD) (3 arms), sponsored by Islamic Azad University. Primary endpoints: HbA1c level, Fasting blood sugar level and 1 more. Started Sep 2024; status: completed.
02
Drugs
citalopramescitalopramsertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20240911063012N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240911063012N1.